CANY
DYN icon

Caxton Associates (New York)’s Dyne Therapeutics DYN Stock Holding History

Caxton Associates (New York)’s Portfolio DYN Stock Details DYN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q2 		– Sell
-37,501
Closed -$432K – 540
2023
Q1 		$432K Buy
37,501
+1,141
+3% +$14.8K 0.07% 287
2022
Q4 		$421K Buy
+36,360
New +$421K 0.03% 271

Other funds holding DYN

AVLSA
Atlas Venture Life Science Advisors Cambridge, Massachusetts $790M AUM 223.66% 1-Year Est. Return
MAM
MPM Asset Management Boston, Massachusetts $44.5M AUM 47.28% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
WA
Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return
VVA
Vida Ventures Advisors Boston, Massachusetts $29.4M AUM 93.58% 1-Year Est. Return
VA
VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Caxton Associates (New York)'s DYN Position: Q2 2023 in Review

Caxton Associates (New York) sold out of Dyne Therapeutics (DYN) in Q2 2023, closing a stake of 37,501 shares — an estimated $432K sold.

Caxton Associates (New York) first reported a position in DYN in Q4 2022 and held it in 2 quarters. The position peaked at $432K in Q1 2023. 118 funds tracked by Wall St. Rank hold DYN as of Q2 2023.

  • Caxton Associates (New York) reported no remaining Dyne Therapeutics position as of Q2 2023 after selling out during the quarter.
  • Caxton Associates (New York) sold 37,501 Dyne Therapeutics shares in Q2 2023, an estimated $432K.
  • Caxton Associates (New York) first reported a position in Dyne Therapeutics in Q4 2022 and held it in 2 quarters.
  • Caxton Associates (New York)'s Dyne Therapeutics position peaked at $432K in Q1 2023.
  • 118 funds tracked by Wall St. Rank held Dyne Therapeutics as of Q2 2023.

Based on Caxton Associates (New York)'s 13F filing for Q2 2023, filed 15 Aug 2023.